• Praveena Velpurisiva
  • Janel L. Kydd
  • Rahul Jadia
  • Stephanie A. MorrisEmail author
  • Prakash RaiEmail author
Part of the Bioanalysis book series (BIOANALYSIS, volume 5)


Traditional medicine has been in use since ancient times to treat various forms of illness. The modern practice of medicine has evolved into advanced surgery, endoscopy, laser treatments, radiation therapies, and chemotherapies. Newer modalities of treatment include immunotherapies and genetic therapies that aim to be molecularly targeted to a patient’s disease. These advancements have enhanced healthcare leading to improved treatment outcomes. However, these forms of treatments tend to be invasive and pose side effects due to their non-specificity for the diseased tissue. Since existing options do not provide a go-to solution for every disease, some of the emerging pharmacological technologies focus on providing personalized and targeted treatments that minimize toxic effects while effectively treating the illness. Success stories in drug discovery have led us to identify a vast library of therapeutics that can be very effective in in vitro and in vivo models of diseases but often fail to produce the desired response in humans. Maladies that continue to plague mankind are considered caused by “drug delivery problems” as opposed to “drug discovery problems,” which have been conventionally thought of as root sources of failure in successful disease-ameliorative measures. Delivering the “right drug” to the “right place” at the “right time” in the “right dose” could help improve treatment outcomes across all disease types. As Sir Richard Feynman had envisioned the field of nanotechnology in the mid-twentieth century, key nanoscale properties like high surface area to volume ratio and smaller size have revolutionized various fields like drug delivery, diagnostics, 3D printing, cosmetics development, food processing, nano-fertilization for agriculture, miniaturization of chips and semiconductors in electronic devices, composite coatings for automobiles, and decontamination of water and soil. Nanoscale materials vary from bulk or macroscale materials in their mechanical, electrical, optical, and magnetic properties. Exploiting these properties in nanomaterials for applications in medicine, referred to as nanomedicine, can address concerns about the location, time, dose, and ability to deliver the most appropriate drug and will be the focus of this book.


Nanotechnology Nanomedicine Nanotheranostics Nanodiagnostics Nanotherapeutics Cancer Oncology Targeted Personalized medicine Theranostics Smart medicine Drug delivery systems Infectious diseases Cardiovascular diseases Neurodegenerative diseases Clinical Translational Surface modification Zeta potential Multifunctional Chemotherapeutic drugs Contrast agents Photosensitizers Nanodevices 


  1. 1.
    Shanks, N., Greek, R., Greek, J.: Are animal models predictive for humans? Philos. Ethics Humanit. Med. 4, 2 (2009)CrossRefGoogle Scholar
  2. 2.
    Feynman, R.P.: There’s plenty of room at the bottom: An invitation to enter a new field of physics, in the handbook of nanoscience, engineering, and technology, 3rd edn, pp. 26–35. CRC Press (2012)Google Scholar
  3. 3.
    Schaming, D., Remita, H.: Nanotechnology: from the ancient times to nowadays. Found. Chem. 17(3), 187–205 (2015)CrossRefGoogle Scholar
  4. 4.
    Cao, G.: Nanostructures & nanomaterials: synthesis, properties & applications. Imperial College Press (2004)Google Scholar
  5. 5.
    Abraham, M.K., et al.: Nanoliposomes for safe and efficient therapeutic mRNA delivery: a step toward nanotheranostics in inflammatory and cardiovascular diseases as well as cancer. Nanotheranostics. 1(2), 154–165 (2017)MathSciNetCrossRefGoogle Scholar
  6. 6.
    Yhee, J.Y., et al.: Self-assembled glycol chitosan nanoparticles for disease-specific theranostics. J. Control. Release. 193, 202–213 (2014)CrossRefGoogle Scholar
  7. 7.
    Kumar, P., et al.: Preclinical explorative assessment of dimethyl fumarate-based biocompatible nanolipoidal carriers for the management of multiple sclerosis. ACS Chem. Neurosci. 9, 1152 (2018)CrossRefGoogle Scholar
  8. 8.
    Muthu, M.S., Mehata, A.K., Viswanadh, M.K.: Upconversion nanotheranostics: emerging designs for integration of diagnosis and therapy. Nanomedicine (Lond.). 12(6), 577–580 (2017)CrossRefGoogle Scholar
  9. 9.
    Varna, M., Xuan, H.V., Fort, E.: Gold nanoparticles in cardiovascular imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 10(1), e1470 (2018)CrossRefGoogle Scholar
  10. 10.
    Bolognesi, M.L., et al.: From companion diagnostics to theranostics: a new avenue for Alzheimer's disease? J. Med. Chem. 59(17), 7759–7770 (2016)CrossRefGoogle Scholar
  11. 11.
    Chuang, S.Y., et al.: Lipid-based nanoparticles as a potential delivery approach in the treatment of rheumatoid arthritis. Nanomaterials (Basel). 8(1), 42 (2018)CrossRefGoogle Scholar
  12. 12.
    Mieszawska, A.J., et al.: Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10(3), 831–847 (2013)CrossRefGoogle Scholar
  13. 13.
    Rial, M.S., et al.: Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. PLoS Negl. Trop. Dis. 11(12), e0006119 (2017)CrossRefGoogle Scholar
  14. 14.
    Sonali, et al.: Nanotheranostics: emerging strategies for early diagnosis and therapy of brain cancer. Nanotheranostics. 2(1), 70–86 (2018)CrossRefGoogle Scholar
  15. 15.
    Scaria, P.V., et al.: Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity. PLoS One. 12(12), e0190312 (2017)CrossRefGoogle Scholar
  16. 16.
    Singh, R.K., et al.: Progress in nanotheranostics based on mesoporous silica nanomaterial platforms. ACS Appl. Mater. Interfaces. 9(12), 10309–10337 (2017)CrossRefGoogle Scholar
  17. 17.
    Hajipour, M.J., et al.: Sensing of Alzheimer's disease and multiple sclerosis using nano-bio interfaces. J. Alzheimers Dis. 59(4), 1187–1202 (2017)CrossRefGoogle Scholar
  18. 18.
    Liu, Y., et al.: Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice. Biomaterials. 80, 33–45 (2016)CrossRefGoogle Scholar
  19. 19.
    Zhou, B., et al.: Targeted tumor dual mode CT/MR imaging using multifunctional polyethylenimine-entrapped gold nanoparticles loaded with gadolinium. Drug Deliv. 25(1), 178–186 (2018)CrossRefGoogle Scholar
  20. 20.
    Wang, Y., et al.: Optimization of the composition and dosage of PEGylated polyethylenimine-entrapped gold nanoparticles for blood pool, tumor, and lymph node CT imaging. Mater. Sci. Eng. C Mater. Biol. Appl. 83, 9–16 (2018)CrossRefGoogle Scholar
  21. 21.
    Kania, G., et al.: Uptake and bioreactivity of charged chitosan-coated superparamagnetic nanoparticles as promising contrast agents for magnetic resonance imaging. Nanomedicine. 14(1), 131–140 (2018)CrossRefGoogle Scholar
  22. 22.
    Kostevsek, N., et al.: Hybrid FePt/SiO2/Au nanoparticles as a theranostic tool: in vitro photo-thermal treatment and MRI imaging. Nanoscale. 10(3), 1308–1321 (2018)CrossRefGoogle Scholar
  23. 23.
    Luo, Y., et al.: “One-pot” fabrication of highly versatile and biocompatible poly(vinyl alcohol)-porphyrin-based nanotheranostics. Theranostics. 7(16), 3901–3914 (2017)CrossRefGoogle Scholar
  24. 24.
    Haney, K., et al.: The role of affordable, point-of-care technologies for cancer care in low- and middle-income countries: a review and commentary. IEEE J. Transl. Eng. Health Med. 5, 2800514 (2017)CrossRefGoogle Scholar
  25. 25.
    Kazura, E., et al.: Nano-calorimetry based point of care biosensor for metabolic disease management. Biomed. Microdevices. 19(3), 50 (2017)CrossRefGoogle Scholar
  26. 26.
    Fan, Y., et al.: Engineering a brain cancer chip for high-Throughput drug screening. Sci Rep. 6, 25062 (2016)CrossRefGoogle Scholar
  27. 27.
    Hammond, P.T.: Nano tools pave the way to new solutions in infectious disease. ACS Infect. Dis. 3(8), 554–558 (2017)CrossRefGoogle Scholar
  28. 28.
    Kaushal, A., et al.: Nano-Au/cMWCNT modified speB gene specific amperometric sensor for rapidly detecting streptococcus pyogenes causing rheumatic heart disease. Indian J. Microbiol. 57(1), 121–124 (2017)CrossRefGoogle Scholar
  29. 29.
    Tharwat, M.M., et al.: Ultra-sensitive nano optical sensor samarium-doxycycline doped in sol gel matrix for assessment of glucose oxidase activity in diabetics disease. J. Fluoresc. 27(5), 1885–1895 (2017)CrossRefGoogle Scholar
  30. 30.
    de Fougerolles, A., et al.: Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443–453 (2007)CrossRefGoogle Scholar
  31. 31.
    Therapeutics S. FDA advisory committee unanimously recommends approval of investigational Luxturna™(voretigene neparvovec) for patients with biallelic RPE65-mediated inherited retinal disease. 2017-10-12)[2017-12-05]. Link:
  32. 32.
    Carradori, D., et al.: Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model. Nanomedicine. 14(2), 609–618 (2017)CrossRefGoogle Scholar
  33. 33.
    Sanchez-Ramos, J., Song, S., Kong, X., Foroutan, P., Martinez, G., Dominguez-Viqueria, W., Mohapatra, S., Mohapatra, S., Haraszti, R.A., Khvorova, A., Aronin, N., Sava, V.: Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. J. Drug Deliv. Sci. Technol. 43, 453–460 (2018)CrossRefGoogle Scholar
  34. 34.
    Gunday Tureli, N., et al.: Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur. J. Pharm. Biopharm. 117, 363–371 (2017)CrossRefGoogle Scholar
  35. 35.
    Vieira, A.C., et al.: Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. Nanomedicine (Lond.). 12(24), 2721–2736 (2017)CrossRefGoogle Scholar
  36. 36.
    Kunwoo Lee, M.C., Park, H.M., Jiang, F., Kim, H.J., Dewitt, M.A., Mackley, V.A., Chang, K., Rao, A., Skinner, C., Shobha, T., Mehdipour, M., Liu, H., Huang, W.-c., Lan, F., Lan, N., Bray, N.L., Li, S., Corn, J.E., Kataoka, K., Doudna, J.A., Conboy, I., Murthy, N.: Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017)CrossRefGoogle Scholar
  37. 37.
    Zhang, M., et al.: Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 101, 321–340 (2016)CrossRefGoogle Scholar
  38. 38.
    Yang, C., et al.: Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice. Theranostics. 5(2), 110–123 (2015)CrossRefGoogle Scholar
  39. 39.
    Hanes JS, Pan Q, Xu Q, Boylan NJ, Stark WJ, Wang B, Luo L, inventors; Johns Hopkins University, assignee. Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization. United States patent application US 15/502,732. 2017 Jun 8.Google Scholar
  40. 40.
    Lee, G.Y., et al.: Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials. 53, 341–348 (2015)CrossRefGoogle Scholar
  41. 41.
    Vacas-Cordoba, E., et al.: Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides. Int. J. Nanomedicine. 9, 3591–3600 (2014)Google Scholar
  42. 42.
    Wen, X., et al.: Nanomedicine strategy for optimizing delivery to outer hair cells by surface-modified poly(lactic/glycolic acid) nanoparticles with hydrophilic molecules. Int. J. Nanomedicine. 11, 5959–5969 (2016)CrossRefGoogle Scholar
  43. 43.
    Sundar, S., Chakravarty, J.: Liposomal amphotericin B and leishmaniasis: dose and response. J. Glob. Infect. Dis. 2(2), 159–166 (2010)CrossRefGoogle Scholar
  44. 44.
    Deng, L., et al.: Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat. Commun. 9(1), 359 (2018)MathSciNetCrossRefGoogle Scholar
  45. 45.
    Kirtane, A.R., et al.: Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat. Commun. 9(1), 2 (2018)CrossRefGoogle Scholar
  46. 46.
    Courtney, C.M., et al.: Potentiating antibiotics in drug-resistant clinical isolates via stimuli-activated superoxide generation. Sci. Adv. 3(10), e1701776 (2017)CrossRefGoogle Scholar
  47. 47.
    Pan, J., et al.: Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles. Sci. Rep. 8(1), 1117 (2018)CrossRefGoogle Scholar
  48. 48.
    Jeong, J.W., et al.: Wireless optofluidic systems for programmable in vivo pharmacology and optogenetics. Cell. 162(3), 662–674 (2015)CrossRefGoogle Scholar
  49. 49.
    Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017)CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.Department of Biomedical Engineering and BiotechnologyUniversity of Massachusetts LowellLowellUSA
  2. 2.National Cancer Institute, NIH, Nanodelivery Systems and Devices Branch, Cancer Imaging Program, Division of Cancer Treatment and DiagnosisRockvilleUSA
  3. 3.Department of Chemical EngineeringUniversity of Massachusetts LowellLowellUSA

Personalised recommendations